Subramani Baskar, Pullai Chithra Ramanathan, Krishnan Kohila, Sugadan Sheela Devi, Deng Xuewen, Hiroshi Terunuma, Ratnavelu Kananathan
Nichi-Asia Life Science, Sdn. Bhd., Petaling Jaya 47810, Malaysia.
Biotherapy Institute of Japan, Tokyo 135-0051, Japan.
Biomed Rep. 2014 Jul;2(4):505-508. doi: 10.3892/br.2014.264. Epub 2014 Mar 26.
Immune cell-based therapies using natural killer (NK) cells and cytotoxic T cells are under constant scrutiny, with the aim to design an effective and reduced-toxicity therapy, which will benefit patients via improved quality of life and improved prognosis. Four patients with stage IV colon cancer were administered 1, 3, 5 and 6 effector cell intravenous infusions, respectively. Peripheral blood was collected from the patients and the activation and expansion of NK and T cells was performed in Good Manufacturing Practice-certified clean rooms for ~12-15 days. Immunophenotypic analysis of the peripheral blood mononuclear cells (PBMCs) and expanded NK and T cells was conducted using flow cytometry and the patients were followed up. On average, 4.8×10 initial PBMCs and 2.7×10 total expanded cells were obtained. The intravenous infusions of the expanded cells were not accompanied by adverse reactions. Improved prognosis, reflected by a considerable decrease in the cancer markers, accompanied by an improved quality of life in the patients were observed. In conclusion, potential strategies are currently under development for the large-scale production of effectors cells; therefore, autologous immune enhancement therapy (AIET) may be considered as a viable approach to cancer treatment.
使用自然杀伤（NK）细胞和细胞毒性T细胞的基于免疫细胞的疗法一直受到密切关注，目的是设计一种有效且毒性降低的疗法，通过改善生活质量和预后使患者受益。分别对4例IV期结肠癌患者进行了1、3、5和6次效应细胞静脉输注。从患者采集外周血，并在符合药品生产质量管理规范（GMP）认证的洁净室中对NK和T细胞进行激活和扩增约12 - 15天。使用流式细胞术对外周血单个核细胞（PBMC）以及扩增后的NK和T细胞进行免疫表型分析，并对患者进行随访。平均获得4.8×10个初始PBMC和2.7×10个总扩增细胞。扩增细胞的静脉输注未伴随不良反应。观察到癌症标志物显著下降反映出预后改善，同时患者生活质量也得到改善。总之，目前正在开发用于大规模生产效应细胞的潜在策略；因此，自体免疫增强疗法（AIET）可被视为一种可行的癌症治疗方法。
